Bio-Matrix Scientific Group Inc Information

Bio-Matrix Scientific Group, Inc., through its subsidiary, Regen BioPharma, Inc., is engaged in the development of regenerative medical applications. The Company focuses on licensing from other entities up to the point of successful completion of Phase I and or Phase II clinical trials, after which it intends to sell or license those developed applications or advance the application further to Phase III clinical trials. Its products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax and Small Molecules. The Company is focused on the development of HemaXellerate I, a cellular therapy designed to heal damaged bone marrow. HemaXellerate II is intended to be a universal donor endothelial cell-based therapeutic. dCellVax is intended to be a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is intended to be an autologous cellular product. The Company identifies small molecules via a high throughput screening program.